Core Viewpoint - Invenra Bio (09606) has seen a significant increase in stock price following its inclusion in the Hang Seng Composite Index and the Hong Kong Stock Connect, indicating strong market recognition of the company's performance and value [1] Group 1: Stock Performance - The stock price of Invenra Bio rose over 8% in early trading and is currently up 3.97%, trading at 418.8 HKD with a transaction volume of 133 million HKD [1] Group 2: Index Inclusion - Starting from September 8, Invenra Bio has officially been included in the Hang Seng Composite Index and the eligible securities for the Hong Kong Stock Connect, which is expected to broaden the company's investor base and enhance trading liquidity [1] Group 3: Clinical Trial Results - An independent data monitoring committee (IDMC) has evaluated that the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients has met its primary endpoint of progression-free survival (PFS) [1] - Following the interim analysis results, the company plans to communicate with the National Medical Products Administration (NMPA) in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]
映恩生物早盘涨超8% 昨日起正式进入港股通名单 HER2 ADC乳腺癌III期研究成功